Koselugo(selumetinib)
Koselugo (selumetinib) is a small molecule pharmaceutical. Selumetinib was first approved as Koselugo on 2020-04-10. It is used to treat neurofibromatosis 1 in the USA. It has been approved in Europe to treat neurofibromatosis 1. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Koselugo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Selumetinib sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KOSELUGO | AstraZeneca | N-213756 RX | 2020-04-10 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| koselugo | New Drug Application | 2024-01-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neurofibromatosis 1 | — | D009456 | Q85.01 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SELUMETINIB SULFATE, KOSELUGO, ASTRAZENECA | |||
| 2027-04-10 | ODE-288 | ||
| 2025-04-10 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
138 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 9 | 11 | 1 | — | 1 | 20 |
| Lung neoplasms | D008175 | — | C34.90 | 8 | 9 | 1 | — | 1 | 18 |
| Neurofibromatoses | D017253 | — | Q85.00 | 6 | 5 | 1 | — | 5 | 15 |
| Neurofibroma | D009455 | EFO_0000622 | — | 6 | 4 | 1 | — | 5 | 14 |
| Neurofibromatosis 1 | D009456 | — | Q85.01 | 6 | 5 | 1 | — | 3 | 13 |
| Plexiform neurofibroma | D018318 | EFO_0000658 | — | 4 | 2 | 1 | — | 3 | 9 |
| Melanoma | D008545 | — | — | 4 | 2 | 1 | — | — | 7 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | 1 | — | 1 | 3 |
| Small cell lung carcinoma | D055752 | — | — | — | 1 | 1 | — | — | 2 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | — | 1 | — | — | 2 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 9 | 2 | — | — | — | 10 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 3 | — | — | — | 6 |
| Colorectal neoplasms | D015179 | — | — | 2 | 3 | — | — | — | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | — | — | — | 4 |
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
| Squamous cell neoplasms | D018307 | — | — | 1 | 2 | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 2 | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 2 | — | — | — | 2 |
| Squamous cell carcinoma | D002294 | — | — | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 3 | — | — | — | — | 3 |
| Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | 1 | — | — | — | — | 1 |
| Male genital neoplasms | D005834 | — | — | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Selumetinib |
| INN | selumetinib |
| Description | Selumetinib is a member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent and an anticoronaviral agent. It is a member of benzimidazoles, a hydroxamic acid ester, a member of monochlorobenzenes, a member of bromobenzenes, an organofluorine compound and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 606143-52-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1614701 |
| ChEBI ID | 90227 |
| PubChem CID | 10127622 |
| DrugBank | DB11689 |
| UNII ID | 6UH91I579U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
BRAF
BRAF
Organism
Homo sapiens
Gene name
BRAF
Gene synonyms
BRAF1, RAFB1
NCBI Gene ID
Protein name
serine/threonine-protein kinase B-raf
Protein synonyms
94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, p94, Proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1
Uniprot ID
Mouse ortholog
Braf (109880)
serine/threonine-protein kinase B-raf (P28028)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Koselugo – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,106 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
886 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use